MRI Biomarkers in ALS

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02405182
• Other study ID #: RES0013831
• Status: Completed
• Start date: September 2014
• Est. completion date: April 1, 2019

Study information

• Verified date: December 2020
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk factor for developing ALS; thus, the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately measure brain degeneration in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in this respect, and may assist in aiding diagnosis and the efficient testing of new drugs. Different MRI features of brain degeneration will be measured in a large sample of patients with ALS. The study will operate within the Canadian ALS Neuroimaging Consortium (CALSNIC). CALSNIC is a clinical research platform comprised of ALS clinics with standardized clinical and neuroimaging protocols.

Description:

This study will use advanced Magnetic Resonance Imaging (MRI) techniques to measure brain changes in ALS and related neurological conditions. Results from cognitive and neurological tests will be compared to the MRI. It is believed that these techniques will reveal changes in the brain that will help us understand normal brain function and the symptoms of neurological diseases as seen in ALS, as well to provide an objective measurement of degeneration (which is called a biomarker). This could improve not only the process by which new drugs for the treatment of neurological diseases are evaluated, but also how health care professionals address the needs of patients with these diseases. Furthermore, a biomarker may give insight into the biological factors related to the diverse and variable clinical features amongst different patients. Subjects will be recruited from ALS clinics that are a part of the Canadian ALS Neuroimaging Consortium (CALSNIC). Patients will have a diagnosis of ALS, PLS, PMA, or FTD. Healthy controls will be age and gender matched to patients. Subjects will visit their respective sites to undergo a clinical evaluation and an MRI. Follow up visits will occur at approximately 3-6 month intervals. Most subjects will have 2 follow up visits; more visits may occur for subjects who are physically able to continue in the protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 145
• Est. completion date: April 1, 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients will be adults with a diagnosis of motor neuron disease (MND), including those with ALS, PLS, and PMA, and as well frontotemporal dementia (FTD) without motor neuron signs.
• Healthy controls over the age of 40 will also be recruited and will be age- and gender-matched to patients.

Exclusion Criteria:

• Subjects with other psychiatric/CNS illnesses such as Major Depressive Disorder, Schizophrenia, and Bipolar disorder, and those with significant head injury.
• Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan. These exclusion criteria will also apply to controls.

Related Conditions & MeSH terms

• ALS
• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Motor Neuron Diseases
• Sclerosis

Intervention

Other:
• Magnetic Resonance Imaging

Locations

Country	Name	City	State
Canada	University of Calgary / Heritage Medical Research Clinic	Calgary	Alberta
Canada	University of Alberta	Edmonton	Alberta
Canada	Western University / London Health Sciences Centre	London	Ontario
Canada	McGill University / Montreal Neurological Institute and Hospital	Montreal	Quebec
Canada	University of Toronto / Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	University of British Columbia / GF Strong Rehab Centre	Vancouver	British Columbia

Sponsors (5)

Lead Sponsor	Collaborator
University of Alberta	McGill University, University of Calgary, University of Toronto, Western University, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in neuronal and white matter integrity measures.	The primary analysis will evaluate changes in the brain using various advanced MRI techniques at baseline and specified follow up periods. Patients and controls scans will be compared.	24 months
Secondary	Correlation of neuronal and white matter integrity measures with clinical indices.	Secondary analyses will involve MRI comparison to clinical measures both at the time of the baseline scan and over time.	30 months